Cargando…

Biomodulatory Treatment Regimen, MEPED, Rescues Relapsed and Refractory Classic Hodgkin’s Disease

Introduction: Current combined intensive chemotherapy and radiation regimens yield excellent survival rates in advanced classic Hodgkin’s lymphoma (cHL). However, acute toxicity in elderly, comorbid patients can be challenging and long-term survival in refractory patients remains poor. Patients and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lüke, Florian, Harrer, Dennis C., Menhart, Karin, Wolff, Daniel, Holler, Ernst, Hellwig, Dirk, Herr, Wolfgang, Grube, Matthias, Vogelhuber, Martin, Reichle, Albrecht, Heudobler, Daniel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8249731/ https://www.ncbi.nlm.nih.gov/pubmed/34220492 http://dx.doi.org/10.3389/fphar.2021.599561

Ejemplares similares

Successful Treatment of Early Relapsed High-Risk AML After Allogeneic Hematopoietic Stem Cell Transplantation With Biomodulatory Therapy
por: Kattner, Anna-Sophia, et al.
Publicado: (2020)

Cutaneous Leukemic Infiltrates Successfully Treated With Biomodulatory Therapy in a Rare Case of Therapy-Related High Risk MDS/AML
por: Heudobler, Daniel, et al.
Publicado: (2018)

All-oral low-dose chemotherapy TEPIP is effective and well-tolerated in patients with peripheral T-cell lymphoma
por: Fante, Matthias A., et al.
Publicado: (2023)

Case Report: Extramedullary Acute Promyelocytic Leukemia: An Unusual Case and Mini-Review of the Literature
por: Harrer, Dennis Christoph, et al.
Publicado: (2022)

Unusual Late Relapse of ALK-Positive Anaplastic Large Cell Lymphoma Successfully Cleared Using the ALK-Inhibitor Crizotinib: Case Report
por: Harrer, Dennis Christoph, et al.
Publicado: (2020)

Biomodulatory metronomic therapy in stage IV melanoma is well‐tolerated and may induce prolonged progression‐free survival, a phase I trial
por: Hart, C., et al.
Publicado: (2015)

Gemcitabine Maintenance Therapy in Patients With Metastasized Soft Tissue Sarcomas
por: Harrer, Dennis Christoph, et al.
Publicado: (2021)

Continuous Complete Remission in Two Patients with Acute Lymphoblastic Leukemia and Severe Fungal Infection Following Short-Term, Dose-Reduced Chemotherapy
por: Lüke, Florian, et al.
Publicado: (2021)

Biomodulatory Treatment of Patients with Castration-Resistant Prostate Cancer: A Phase II Study of Imatinib with Pioglitazone, Etoricoxib, Dexamethasone and Low-Dose Treosulfan
por: Vogelhuber, M., et al.
Publicado: (2014)

Peroxisome Proliferator-Activated Receptors (PPAR)γ Agonists as Master Modulators of Tumor Tissue
por: Heudobler, Daniel, et al.
Publicado: (2018)

Biomodulatory Treatment With Azacitidine, All-trans Retinoic Acid and Pioglitazone Induces Differentiation of Primary AML Blasts Into Neutrophil Like Cells Capable of ROS Production and Phagocytosis
por: Klobuch, Sebastian, et al.
Publicado: (2018)

Anakoinosis: Communicative Reprogramming of Tumor Systems - for Rescuing from Chemorefractory Neoplasia
por: Hart, Christina, et al.
Publicado: (2015)

Anakoinosis: Correcting Aberrant Homeostasis of Cancer Tissue—Going Beyond Apoptosis Induction
por: Heudobler, Daniel, et al.
Publicado: (2019)

All-Oral Low-Dose Chemotherapy TEPIP is Effective and Well-Tolerated in Relapsed/Refractory Patients With Aggressive B-Cell Lymphoma
por: Fante, Matthias A., et al.
Publicado: (2022)

Case Report: Dual Checkpoint Inhibition in Advanced Metastatic Osteosarcoma Results in Remission of All Tumor Manifestations—A Report of a Stunning Success in a 37-Year-Old Patient
por: Sterz, Ulrich, et al.
Publicado: (2021)

Editorial: Tumor Systems Biology: How to Therapeutically Redirect Dysregulated Homeostasis in Tumor Systems (i.e., Anakoinosis)
por: Reichle, Albrecht, et al.
Publicado: (2020)

Clinical Efficacy of a Novel Therapeutic Principle, Anakoinosis
por: Heudobler, Daniel, et al.
Publicado: (2018)

Unusually swift response of relapsed Burkitt leukemia to R‐DHAP
por: Harrer, Dennis Christoph, et al.
Publicado: (2022)

Editorial: Anakoinosis: An Innovative Anticancer Therapy Targeting the Aberrant Cancer Tissue Homeostasis
por: Heudobler, Daniel, et al.
Publicado: (2021)

Editorial: Anakoinosis for promoting tumor tissue editing: Novel therapeutic opportunities for establishing clinically relevant tumor control by targeting tumor plasticity
por: Heudobler, Daniel, et al.
Publicado: (2022)

Low-dose trofosfamide plus rituximab is an effective and safe treatment for diffuse large B-cell lymphoma of the elderly: a single center experience
por: Schelker, Roland Christian, et al.
Publicado: (2018)

Drug Repurposing by Tumor Tissue Editing
por: Lüke, Florian, et al.
Publicado: (2022)

Inhibition of Osteoclastogenesis by Mechanically Loaded Osteocytes: Involvement of MEPE
por: Kulkarni, Rishikesh N., et al.
Publicado: (2010)

MEPE is a novel regulator of growth plate cartilage mineralization
por: Staines, K.A., et al.
Publicado: (2012)

A New MEPED‐Based Precipitating Electron Data Set
por: Pettit, Joshua M., et al.
Publicado: (2021)

Calcium-dependent activation of PHEX, MEPE and DMP1 in osteocytes
por: Donmez, Baris Ozgur, et al.
Publicado: (2022)

Coronavirus disease 2019 induces multi‐lineage, morphologic changes in peripheral blood cells
por: Lüke, Florian, et al.
Publicado: (2020)

A Randomized Phase II Trial Comparing the Efficacy and Safety of Pioglitazone, Clarithromycin and Metronomic Low-Dose Chemotherapy with Single-Agent Nivolumab Therapy in Patients with Advanced Non-small Cell Lung Cancer Treated in Second or Further Line (ModuLung)
por: Heudobler, Daniel, et al.
Publicado: (2021)

MEPE loss-of-function variant associates with decreased bone mineral density and increased fracture risk
por: Surakka, Ida, et al.
Publicado: (2020)

MEPE/OF45 as a new target for sensitizing human tumour cells to DNA damage inducers
por: Zhang, P, et al.
Publicado: (2010)

FAM20C‐Mediated Phosphorylation of MEPE and Its Acidic Serine‐ and Aspartate‐Rich Motif
por: Christensen, Brian, et al.
Publicado: (2020)

Acquired Natural Killer Cell Dysfunction in the Tumor Microenvironment of Classic Hodgkin Lymphoma
por: Chiu, Jodi, et al.
Publicado: (2018)

BEGEV salvage regimen in relapsed/refractory classical Hodgkin lymphoma: a real-life experience
por: Stefoni, Vittorio, et al.
Publicado: (2022)

MEPE/OF45 protects cells from DNA damage induced killing via stabilizing CHK1
por: Liu, Shuang, et al.
Publicado: (2009)

P102: Comparison of Novel Salvage Regimens and Traditional salvage Chemotherapy in Relapsed and Refractory Classic Hodgkin Lymphoma
por: Shah, Harsh, et al.
Publicado: (2022)

Retraction of ‘MEPE/OF45 protects cells from DNA damage induced killing via stabilizing CHK1’
Publicado: (2022)

Genetics of classical Hodgkin Lymphoma
por: Schiavoni, Gianluca, et al.
Publicado: (2018)

Impact of chronic graft-versus-host disease on quality of life and cognitive function of long-term transplant survivors after allogeneic hematopoietic stem cell transplantation with total body irradiation
por: Gruber, Isabella, et al.
Publicado: (2022)

P1079: COMPARISON OF NOVEL SALVAGE REGIMENS AND TRADITIONAL SALVAGE CHEMOTHERAPY IN RELAPSED AND REFRACTORY CLASSIC HODGKIN LYMPHOMA
por: Ermann, D., et al.
Publicado: (2022)

CD20 Over-Expression in Hodgkin-Reed-Sternberg Cells of Classical Hodgkin Lymphoma: the Neglected Quest
por: Benharroch, Daniel, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_4k16d0k2ooh9dfce9h8u4ndlei